We are live on ! Find out more
NVCT icon

Nuvectis Pharma
NVCT

53 hedge funds and large institutions have $22.2M invested in Nuvectis Pharma in 2025 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 13 increasing their positions, 15 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

120% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 5

13% more funds holding

Funds holding: 47 → 53 (+6)

1.01% less ownership

Funds ownership: 15.52% → 14.51% (-1%)

8% less capital invested

Capital invested by funds: $24.2M → $22.2M (-$1.97M)

13% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 15

Holders
53
Holders Change
+6
Holders Change %
+12.77%
% of All Funds
0.7%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
13
Reduced
15
Closed
5
Calls
$1.01M
Puts
–
Net Calls
+$1.01M
Net Calls Change
+$938K

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$313K
2
Goldman Sachs
Goldman Sachs
New York
+$310K
3
BlackRock
BlackRock
New York
+$291K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$278K
5
IAM
Iridian Asset Management
Connecticut
+$226K

Top Sellers

Rank Fund Capital Flow
1
Marshall Wace
Marshall Wace
United Kingdom
-$364K
2
Millennium Management
Millennium Management
New York
-$233K
3
BBI
Baxter Bros Inc
Connecticut
-$112K
4
MG
Marex Group
-$112K
5
GCP
GSA Capital Partners
United Kingdom
-$108K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$4.21M +$219K +31,903 +5%
BlackRock
2
BlackRock
New York
$4.13M +$291K +42,355 +7%
IAM
3
Iridian Asset Management
Connecticut
$2.44M +$226K +32,904 +9%
BWP
4
Baldwin Wealth Partners
Massachusetts
$2.11M – – –
Geode Capital Management
5
Geode Capital Management
Massachusetts
$1.96M +$278K +40,401 +14%
OCM
6
Occam Crest Management
Connecticut
$1.75M +$1.99M +290,000 New
State Street
7
State Street
Massachusetts
$823K +$159K +23,137 +20%
Northern Trust
8
Northern Trust
Illinois
$642K -$21.8K -3,176 -3%
Susquehanna International Group
9
Susquehanna International Group
Pennsylvania
$547K +$313K +45,605 +101%
OC
10
Oppenheimer & Co
New York
$416K – – –
JMFC
11
J.M. Forbes & Co
Massachusetts
$355K – – –
Goldman Sachs
12
Goldman Sachs
New York
$272K +$310K +45,163 New
Renaissance Technologies
13
Renaissance Technologies
New York
$258K -$1.38K -200 -0.5%
Charles Schwab
14
Charles Schwab
California
$229K – – –
Royal Bank of Canada
15
Royal Bank of Canada
Ontario, Canada
$186K -$1.55K -226 -0.7%
Bank of New York Mellon
16
Bank of New York Mellon
New York
$169K +$5.72K +832 +3%
Jane Street
17
Jane Street
New York
$158K +$181K +26,278 New
UBS Group
18
UBS Group
Switzerland
$153K +$105K +15,211 +148%
GCP
19
GSA Capital Partners
United Kingdom
$141K -$108K -15,710 -40%
AWM
20
Austin Wealth Management
Texas
$119K – – –
Morgan Stanley
21
Morgan Stanley
New York
$111K -$42.5K -6,176 -25%
Two Sigma Investments
22
Two Sigma Investments
New York
$111K +$2.06K +300 +2%
Barclays
23
Barclays
United Kingdom
$111K -$32.6K -4,749 -20%
N
24
Nuveen
North Carolina
$101K – – –
EDRH
25
Edmond de Rothschild Holding
Switzerland
$91.3K – – –
1
2 3

NVCT Hedge Fund Activity: Q3 2025 in Review

53 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Nuvectis Pharma (NVCT) for Q3 2025, worth a combined $22.2M — down 8.1% from $24.2M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new NVCT positions and 5 closed out — a net gain of 6 holders — while 13 added to existing stakes and 15 trimmed.

The largest buyer was Susquehanna International Group, adding an estimated $313K. The largest seller was Marshall Wace, cutting an estimated $364K.

  • 53 institutional investors held Nuvectis Pharma (NVCT) as of Q3 2025, up from 47 in Q2 2025.
  • Funds reported $22.2M of Nuvectis Pharma stock for Q3 2025, down 8.1% quarter-over-quarter.
  • 11 funds opened new Nuvectis Pharma positions in Q3 2025 and 5 closed out, a net change of +6 holders.
  • The largest Nuvectis Pharma buyer in Q3 2025 was Susquehanna International Group, an estimated $313K added.
  • The largest Nuvectis Pharma seller in Q3 2025 was Marshall Wace, an estimated $364K sold.

Based on aggregated 13F filings for Q3 2025.